ORIGINAL ARTICLE
Antithyroid Antibody Levels in Patients with Breast Cancer
More details
Hide details
1
Yüzüncü Yıl University, Faculty of Medicine, Department of Biochemistry, Van, Turkey
2
Yüzüncü Yıl University, Faculty of Medicine, Department of Medical Oncology, Van, Turkey
3
Yüzüncü Yıl University, Faculty of Medicine, Department of Endocrinology, Van, Turkey
4
Yüzüncü Yıl University, Faculty of Medicine, Department of Radiology, Van, Turkey
5
Yüzüncü Yıl University, Faculty of Medicine, Department of Internal Medicine, Van, Turkey
Online publication date: 2004-04-15
Publication date: 2004-04-15
Corresponding author
Haluk Dülger
Yüzüncü Yıl Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Maraş Caddesi, 65300. Van, Turkey
Eur J Gen Med 2004;1(2):11-14
KEYWORDS
ABSTRACT
Breast cancer is a hormone-dependent neoplasm. Conflicting results regarding the clinical
correlation between breast cancer and thyroid diseases have been reported. The aim of this study
was to determine the goiter prevalence, thyroid hormones and antithyroid antibody levels in
patients with breast cancer. For this purpose, thyroid ultrasonography was performed and serum
levels of free triiodothyronine (FT3 ), free thyroxine (FT4 ), thyroid-stimulating hormone (TSH),
anti-thyroid peroxidase antibodies (anti-TPO ab) and anti-thyroglobulin antibodies (anti-TG ab)
were determined in 50 operable breast cancer patients at the time of diagnosis and 30 healthy
individuals as control group. Goiter prevalence was found to be significantly higher in the
study group (50% vs 10%). FT3 , FT4 , and TSH levels of patients were not different compared to
controls, whereas anti-TPO ab and anti-TG ab levels were significantly higher in patients than in
the control group. In conclusion, goiter prevalence and thyroid antibody levels were found to be
increased in breast cancer patients and thyroid functions should be monitored.